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http://dx.doi.org/10.1016/j.chembiol.2012.09.005On a Friday afternoon in 2009, Hans Lo-
land was battling his insurance company
to get into a phase I trial for ponatinib,
an investigational drug for chronic
myeloid leukemia (CML) developed by
Ariad Pharmaceuticals, Inc. (http://www.
ariad.com). Loland, in his early 40s and
an analyst for Microsoft, was to begin
preparations for a bone marrow trans-
plant the following Monday. He had failed
first-line treatment with imatinib mesylate
(Gleevec) and had spent three months on
dasatinib (Sprycel), a second-generation
drug. ‘‘I’m a numbers guy,’’ Loland said.
‘‘If Sprycel failed, I was out of options.’’
Unknown to him, Loland was among
a subset of CML patients who developedAriad’s ponatinib, a synthetic oral TKI, inhibits all the known
Bcr-Abl mutations, including T315I as well as Ph+ALLthe T315I mutation, which no existing
drug could treat.
CML is a rare blood and bone marrow
cancer in which the body overproduces
white blood cells. Some 5000 people in
the U.S. are diagnosed with it annually.
An estimated 26,000 Americans live with
it. But CML is unique because, at least
initially, the disease is driven by one aber-
rant fused gene, Bcr-Abl, which is
produced by a reciprocal translocation
between chromosomes 9 and 22 known
as the Philadelphia chromosome (Ph).
Patients can spend months or years in
the chronic phase, but without effective
treatment, CML can progress to the
accelerated or blast crisis stage, which
can be lethal within weeks. Bcr-Abl is
also responsible for a small percentage
of Philadelphia-positive acute lympho-
blastic leukemia (Ph+ALL).
According to Timothy Clackson, Ph.D,
president of research and development
and chief scientific officer at Cambridge,
Massachusetts-based Ariad Pharmaceu-
ticals, as patients move through years of
therapy, the disease becomes progres-sively less dependent purely on Bcr-Abl.
In the extreme, the cancer goes out of
control and, driven by multiple onco-
genes, turns aggressive. Successive
mutations warp the structure of the onco-
genic protein so that drugs are unable to
bind to the active site in Abl. Over 50
different mutations have been found in
patients who have developed resistance
to imatinib. The more potent second-
generation agents have fewer mutations
that can cause overt resistance.
‘‘For chronic myeloid leukemia, the
hope is to bring the disease into remission
and then control or stabilize that remis-
sion with oral drug therapy,’’ said Dr.
Daniel DeAngelo, an associate professorof medicine in the Harvard Medical
School Adult Leukemia Program, Dana-
Farber Cancer Institute. But no current
CML drug is effective against T315I, the
so-called gatekeeper mutation at the
entry point of the ATP binding site. This
mutation deletes the hydrogen bond and
has other steric effects that prevent
current drugs from binding. Patients who
develop the T315I mutation survive
a median of just under 2 years. Their
only option is a bone marrow transplant.
Novartis’ imatinib, the first targeted
therapy for CML, was approved in
2001. Imatinib is a tyrosine kinase inhib-
itor (TKI) that induces a complete cyto-
genetic (cell-reducing) response in most
chronic stage patients but is ineffective
in accelerated or blast stage CML. Imati-
nib is going off-patent in 2015. More
potent second-generation TKIs, namely,
Bristol-Myers Squibb’s dasatinib, a
SRC/ABL inhibitor, and Novartis’ nilotinib
(Tasigna), were approved for treatment
of chronic CML in 2010. Historically,
TKIs have not been very effective for
treating ALL.Chemistry & Biology 19, September 21, 2012 ªDesigning a Super Molecule
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Ariad’s ponatinib, a synthetic oral TKI,
inhibits all the known Bcr-Abl mutations,
including T315I as well as Ph+ALL. Pona-
tinib binds in the same place as imatinib,
dasatinib and nilotinib. Originally called
AP24534, ponatinib entered human
testing in 2008.
According to Clackson, Ariad designed
the chemical structure of ponatinib by af-
fixing a thin rigid carbon-carbon triple
bond in the ATP binding region and linear
linker moiety to avoid the bulk of the
isoleucine side chain. ‘‘We were able to
get very respectable binding to the other-
wise difficult T315I mutant by designing in
the triple bond,’’ said Clackson. ‘‘Then we
used a few rounds of more traditional
medicinal chemistry to optimize all the
other interactions of the molecule. We
ended up with a subnanomolar potent
inhibitor—more potent than any of the
three approved drugs—of the native
Bcr-Abl with no mutations, but the mole-
cule was able to retain high affinity binding
to any of the point mutants whichwe engi-
neered, including T315I.’’
Testing It Out
Ariad scientists used an accelerated
mutagenesis screen to generate a library
of over a million randomly mutated
leukemia cells and then exposed the cells
to different drug concentrations. What-
ever grew was resistant. ‘‘You can then
go in and sequence the Bcr-Abl gene in
these cells to see if there is a mutation,’’
said Clackson. ‘‘When we did that with
ponatinib and we increased the concen-
tration, when we got to 40 nanomolar,
nothing grew. That had never been seen
with any Bcr-Abl inhibitor, indeed any
kinase inhibitor. Most striking of all is 11
of the 12 patients we tested who had
a T315I mutation had a response.’’
According to Clackson, the phase I trial
in five different centers in the United
States showed that the molecule was2012 Elsevier Ltd All rights reserved 1075
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nently at about a 40 nM threshold, and
suggested paninhibition on patients who
had failed multiple therapies. Pancreatitis
was the dose-limiting toxicity, so dosage
was kept at 45 mg daily. Other effects
including rashes and low platelet and
blood cell counts were linked to the
effects of myeloid suppression. The
longest treated patients from the Phase I
trial have undergone 3 years of therapy
and still show duration of response.
Now fully enrolled, the pivotal phase 2
PACE (Ponatinib Ph+ALL and CML Evalu-
ation) trial commenced September 2010
at approximately 60 global sites. In the
single-arm trial, 444 CML and Ph+ALL
patients resistant or intolerant to dasatinib
or nilotinib or who had the T315I mutation
received 45mg of ponatinib daily. The end
point for chronic phase CML patients was
major cytogenetic response (MCyR); for
everybodyelse itwasmajor hematological
response (maHR). Ninety-three percent
of chronic phase patients were projected
to maintain major cytogenetic response
at 1 year. Patient follow up is ongoing.
In approximately a year’s data reported
at the 2012 meetings of the American
Society of Clinical Oncology (ASCO)
and European Hematology Association
(EHA), MCyR was achieved by 54% of
chronic phase patients, 70% of chronic
phase patients with the T315I mutation,
and 49% of the chronic phase patients
without the T315I mutation, as compared
to the approximately 24% response rate
of patients to prior drugs. ‘‘Two-thirds of
the patients in the PACE trial who ended
the trial in the chronic phase of the
disease had no detectable mutations,
yet we had very robust responses,
including cytogenetic and molecular
responses,’’ said Clackson.
Sixty percent of accelerated phase
CML patients and 35% of blast phase or
Ph+ ALL patients achieved a maHR. Fifty
percent of acute phase CML patients and
33% of blast phase or Ph+ALL patients
with the T315I mutation achieved
a maHR. Side effects were similar to the
phase I trial. About 6% of patients devel-1076 Chemistry & Biology 19, September 21,oped pancreatitis. Other treatment-
related side effects included decreased
platelets (35%), low white blood cells
(16%) and anemia (9%). Ariad filed an
NDA for accelerated approval of ponatinib
for resistant CML at the end of July 2012.
‘‘There is evidence from both the phase
I and the phase 2 trials that there has been
clinical activity in patients with all the
known mutations, but there have also
been patients with those same mutations
that haven’t responded to therapy,’’ said
Dr. Dale Bixby, clinical assistant professor
in the Department of Internal Medicine,
University of Michigan Medical School.
‘‘At the time of resistance, somewhere
between 30%–50% of patients with
chronic CML will have a mutation identi-
fied. The identification of a mutation
does not guarantee that the mutation is
the reason for the resistance. It may be
an innocent bystander.’’
Although the effectiveness of TKIs is
>90%, there is no cure. ‘‘The conventional
wisdom is that it [CML] is due to a Bcr-Abl
positive stem cell that appears to confer
persistence of the disease, yet is refrac-
tory to Bcr-Abl inhibition,’’ said Bixby.
Patients can expect to take ponatinib all
their lives. Recently approved oral
chemotherapeutics cost in the range of
$8,000 a month, according to Bixby.
Going Head to Head
The next step is to bring ponatinib up front
as a first-line treatment. Ariad is now re-
cruiting approximately 500 patients for
the EPIC (Evaluation of Ponatinib versus
Imatinib in Chronic Myeloid Leukemia)
phase 3 randomized clinical trial to
pit ponatinib against imatinib in treat-
ment-naive patients with chronic phase
CML and compare the major molecular
response (MMR), its duration, and the
emergence of resistance. The trial will be
90% powered to detect a 15% absolute
improvement for ponatinib over imatinib
over 12 months.
Ariad on the Runway
If approved, ponatinib would be Ariad’s
first product to market since the com-2012 ª2012 Elsevier Ltd All rights reservedpany’s founding in 1991. Ariad’s former
lead drug developedwithMerck, ridaforo-
limus, an analog of the antibiotic rapamy-
cin to treat sarcomas underwent a phase
3 trial but failed FDA approval in May
2012.
Ariad netted $243million in a December
2011 public offering and is using the
proceeds to take the company global.
Europe and Japan comprise two-thirds
of the estimated $5 billion plus worldwide
market in TKIs for CML. Ariad is methodi-
cally building its commercial infrastruc-
ture in Europe, has applied to the Euro-
pean Medicines Agency for marketing
approval for ponatinib, and announced
the first dosing of patients in Japan. Ariad
also started a compassionate usage
program for ponatinib.
The company’s pipeline also includes
AP1903 for graft versus host disease
and prostate cancer licensed to Bellicum
Pharmaceuticals (http://www.bellicum.
com) and AP26113, a dual inhibitor of
anaplastic lymphoma kinase (ALK) and
epidermal growth factor receptor (EGFR)
in phase I/2 trials for a subset of non-
small-cell lung cancer.
Bosutinib, a dual Src/Abl TKI marketed
as Bosulif by Pfizer, just received FDA
approval for adult patients with chronic,
accelerated, or blast phase (Ph+) CML
resistant or intolerant to prior therapy.
Bosutinib is ineffective against T315I.
Other CML drugs are still in the early
stage, such as Lawrence, Kansas-based
Deciphera’s (http://www.deciphera.com)
DCC-2036, an Abl switch control inhibitor
for Ph+ leukemias and the T315I muta-
tion, in phase 1.
At the last minute, Hans Loland’s insur-
ance agreed to foot the bill for him to enter
the ponatinib study. While Loland still
experiences side effects, in his last blood
test the cancer was undetectable. He will
have to stay on ponatinib the rest of his
life, but his odds are looking better now.
He and his wife recently had a third child,
a son.Wendy Wolfson (wendywolfson@nasw.org) is
a science writer based in the Bay Area.
